<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/dataseer-ml/../grobid-home/schemas/xsd/Grobid.xsd">
  <teiHeader xml:lang="en">
    <encodingDesc>
      <appInfo>
        <application ident="GROBID" version="0.5.6-SNAPSHOT" when="2019-07-08T05:27+0000">
          <ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
        </application>
      </appInfo>
    </encodingDesc>
    <fileDesc>
      <titleStmt>
        <title level="a" type="main">The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review</title>
      </titleStmt>
      <publicationStmt>
        <publisher/>
        <availability status="unknown">
          <licence/>
        </availability>
      </publicationStmt>
      <sourceDesc>
        <biblStruct>
          <analytic>
            <author>
              <persName>
                <forename type="first">Stephen</forename>
                <forename type="middle">Mac</forename>
                <surname>Id</surname>
              </persName>
              <affiliation key="aff0">
                <orgName type="department">Institute of Health Policy, Management and Evaluation</orgName>
                <orgName type="institution">University of Toronto</orgName>
                <address>
                  <settlement>Toronto</settlement>
                  <region>Ontario</region>
                  <country key="CA">Canada</country>
                </address>
              </affiliation>
              <affiliation key="aff1">
                <orgName type="department">Toronto Health Economics and Technology Assessment (THETA) Collaborative</orgName>
                <orgName type="institution">University Health Network</orgName>
                <address>
                  <settlement>Toronto</settlement>
                  <region>Ontario</region>
                  <country key="CA">Canada</country>
                </address>
              </affiliation>
            </author>
            <author>
              <persName>
                <forename type="first">Sara</forename>
                <forename type="middle">R</forename>
                <surname>Da Silva</surname>
              </persName>
              <affiliation key="aff2">
                <orgName type="department">Department of Biology</orgName>
                <orgName type="institution">University of Toronto Mississauga</orgName>
                <address>
                  <settlement>Mississauga</settlement>
                  <region>Ontario</region>
                  <country key="CA">Canada</country>
                </address>
              </affiliation>
            </author>
            <author>
              <persName>
                <forename type="first">Beate</forename>
                <surname>Sander</surname>
              </persName>
              <affiliation key="aff0">
                <orgName type="department">Institute of Health Policy, Management and Evaluation</orgName>
                <orgName type="institution">University of Toronto</orgName>
                <address>
                  <settlement>Toronto</settlement>
                  <region>Ontario</region>
                  <country key="CA">Canada</country>
                </address>
              </affiliation>
              <affiliation key="aff1">
                <orgName type="department">Toronto Health Economics and Technology Assessment (THETA) Collaborative</orgName>
                <orgName type="institution">University Health Network</orgName>
                <address>
                  <settlement>Toronto</settlement>
                  <region>Ontario</region>
                  <country key="CA">Canada</country>
                </address>
              </affiliation>
              <affiliation key="aff3">
                <orgName type="department">Institute for Clinical Evaluative Sciences</orgName>
                <address>
                  <settlement>Toronto</settlement>
                  <region>Ontario</region>
                  <country key="CA">Canada</country>
                </address>
              </affiliation>
              <affiliation key="aff4">
                <orgName type="institution">Public Health Ontario</orgName>
                <address>
                  <settlement>Toronto</settlement>
                  <region>Ontario</region>
                  <country key="CA">Canada</country>
                </address>
              </affiliation>
            </author>
            <title level="a" type="main">The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review</title>
          </analytic>
          <monogr>
            <imprint>
              <date/>
            </imprint>
          </monogr>
          <idno type="DOI">10.1371/journal.pone.0210280</idno>
          <note>RESEARCH ARTICLE</note>
        </biblStruct>
      </sourceDesc>
    </fileDesc>
    <profileDesc>
      <abstract>
        <div/>
      </abstract>
    </profileDesc>
  </teiHeader>
  <text xml:lang="en">
    <body>
      <div>
        <head>Introduction</head>
        <p>
          <s>While Lyme disease (LD) is mostly treatable, misdiagnosed or untreated LD can result in debilitating sequelae and excessive healthcare usage.</s>
          <s>The objective of this review was to characterize the body of literature on the economic burden of Lyme disease (LD) and the cost-effectiveness of LD interventions, such as antibiotic treatment and vaccination.</s>
        </p>
      </div>
      <div>
        <head>Methods</head>
        <p>
          <s>We followed Joanna Briggs Institute scoping review methodologies.</s>
          <s>We systematically searched terms related to LD, economic evaluations, costs, and cost-effectiveness in Medline, Embase, PsycInfo, Cochrane Library, and the grey literature up to November 2017.</s>
          <s>We included primary economic evaluations conducted in North America and Europe, reporting LD-related costs or cost-effectiveness of human interventions.</s>
          <s>Two reviewers screened articles and charted data independently.</s>
          <s>Costs were standardized to 2017 United States dollars (USD).</s>
        </p>
      </div>
      <div>
        <head>Results</head>
        <p>
          <s>We screened 923 articles, and included 10 cost-effectiveness analyses (CEA) and 11 cost analyses (CA).</s>
          <s>Three CEAs concluded LD vaccination was likely cost-effective only in endemic areas (probability of infection �1%).</s>
          <s>However, LD vaccination is not currently available as an intervention in the US or Europe.</s>
          <s>Six studies assessed economic burden from a societal perspective and estimated significant annual national economic impact of: 735,550 USD for Scotland (0.14 USD per capita, population = 5.40M), 142,562 USD in Sweden (0.014 USD per capita, 9.96M), <ref target="#b38" type="bibr">40</ref>
          </s>
        </p>
      </div>
      <div>
        <head>Introduction</head>
        <p>
          <s>Lyme disease (LD), also known as Lyme borreliosis, is an increasingly common vector-borne disease reported in temperate climate zones in North America (NA) and parts of Europe.</s>
          <s>
            <ref target="#b0" type="bibr">[1]</ref>
            <ref target="#b1" type="bibr">[2]</ref>
            <ref target="#b2" type="bibr">[3]</ref> Most human LD infections are caused by three species of bacteria: Borrelia burgdorferi, B. garinii, and B. afzelii <ref target="#b0" type="bibr">[1]</ref> Since 2015, LD has been the most common reportable vector-borne disease in NA and Europe.</s>
          <s>
            <ref target="#b2" type="bibr">[3,</ref>
            <ref target="#b3" type="bibr">4]</ref> Endemic areas in Europe (e.g.</s>
          <s>Slovenia) and the United States (US) (e.g.</s>
          <s>Maine) have reported incidence rates of 130 per 100,000 populations in 2010, and 86.4 per 100,000 populations in 2016, respectively.</s>
          <s>
            <ref target="#b2" type="bibr">[3,</ref>
            <ref target="#b3" type="bibr">4]</ref> Furthermore, current reported rates of LD may be conservative given underreporting estimates of eight to tenfold in the United States.</s>
          <s>
            <ref target="#b0" type="bibr">[1]</ref> The World Health Organization has made LD a priority disease, <ref target="#b4" type="bibr">[5]</ref> as experts predict escalating climate change to play a significant role in the proliferation of this disease due to the expansion of habitable environments for ticks.</s>
          <s>
            <ref target="#b5" type="bibr">[6]</ref> In Canada, the controversies surrounding the clinical management of LD prompted the federal government to commit to addressing the challenges of recognition, timely diagnosis and treatment of LD, mandated by the unprecedented Federal Framework on Lyme Disease Act.</s>
          <s>
            <ref target="#b6" type="bibr">[7]</ref> While mostly treatable, misdiagnosed or untreated LD can result in debilitating long-term sequelae, inappropriate long-term antibiotic therapy and excessive healthcare use.</s>
          <s>
            <ref target="#b7" type="bibr">[8]</ref> There is currently no human LD vaccine available.</s>
          <s>
            <ref target="#b8" type="bibr">[9]</ref> The objective of this review was to systematically gather and characterize the body of literature on the economic burden of LD and the costeffectiveness of LD intervention strategies in order to identify possible knowledge gaps affecting health policy decision-making for LD.</s>
        </p>
      </div>
      <div>
        <head>Methods</head>
        <p>
          <s>This scoping review followed the five-step framework by Arksey and O'Malley with guidance from the Joanna Briggs Institute.</s>
          <s>
            <ref target="#b9" type="bibr">[10,</ref>
            <ref target="#b10" type="bibr">11]</ref> PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed.</s>
          <s>
            <ref target="#b11" type="bibr">[12]</ref> Search strategy A scientific literature search was conducted for English language studies published in four electronic databases from inception to November 2017: Medline In-Process and Other NonIndexed Citations database (Ovid interface), Embase (Ovid interface), PsycInfo (Ovid interface) and the Cochrane Library (Cochrane Central Register of Controlled Trials), Cochrane Database of Systematic Reviews, Health Technology Assessment (HTA) Database, NHS Economic Evaluation Database and Database of Abstracts of Reviews of Effects).</s>
          <s>Search terms were developed in consultation with a faculty librarian at the University of Toronto Libraries and included the concepts: "Lyme disease", "Lyme borreliosis", "healthcare costs", "health economics", "cost-effectiveness analysis", "economic evaluations", "Borrelia infections", and LD stages or manifestations such as: "erythema chronicum migrans", "Lyme neuroborreliosis" and "post-treatment Lyme disease".</s>
          <s>The complete Medline search strategy is presented in S1 Text.</s>
          <s>This strategy was adapted for use in other databases to adjust for database-specific syntax.</s>
        </p>
      </div>
      <div>
        <head>Searching other sources</head>
        <p>
          <s>Reference lists from relevant articles and systematic reviews were manually searched to identify further relevant studies for potential inclusion.</s>
          <s>Grey literature was searched following the Canadian Agency for Drugs and Technology in Health (CADTH) guidelines.</s>
          <s>
            <ref target="#b12" type="bibr">[13]</ref> A total of 48 HTA agencies and health economic organizations in NA and Europe were searched using concepts similar to the electronic database searches.</s>
        </p>
      </div>
      <div>
        <head>Eligibility criteria</head>
        <p>
          <s id="0" type="Tabular data">We included the following eligible economic evaluations: cost-of-illness analysis, cost-minimization analysis, cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis.</s>
          <s>For analysis, we classified studies as a CEA if it included a cost, health and cost-effectiveness outcome (e.g.</s>
          <s>cost per case averted, or cost per quality-adjusted life year (QALY) gained).</s>
          <s>We classified economic evaluations as cost analyses if the outcomes were solely focused on costs (e.g.</s>
          <s>diagnostic, total healthcare, treatment) and if the study was comprehensively conducted using the literature or real-world data.</s>
          <s>
            <ref target="#b13" type="bibr">[14]</ref> Studies reporting a simple cost estimate and/or referencing a primary study were excluded.</s>
          <s>CEA studies that did not evaluate LD-associated interventions for humans were also excluded.</s>
        </p>
        <p>
          <s>Due to the comparable health care systems and the nature of LD, we included studies conducted in NA (Canada and US) and Europe (all 51 countries).</s>
          <s>There were no limitations on the publication date and we searched up until November 8 th , 2017.</s>
          <s>Editorials, reviews, comments, replies, correspondences, viewpoints and protocols were excluded.</s>
          <s>Articles that reported outcomes unrelated to costs, health outcomes and/or economic evaluation outcomes were excluded.</s>
        </p>
      </div>
      <div>
        <head>Study selection</head>
        <p>
          <s>All search results were aggregated and de-duplicated using Mendeley Reference Management Software.</s>
          <s>Abstract and title, and full-text screening were completed independently by two reviewers (SM and SDS).</s>
          <s>Prior to screening, both reviewers conducted a calibration with a set of 100 results.</s>
          <s>Conflicts at any stage of screening were discussed and resolved through consensus.</s>
          <s>Disagreements were resolved by a third reviewer (BS).</s>
          <s>Study selection process and exclusion reasons are shown in <ref target="#fig_1" type="figure">Fig 1.</ref>
          </s>
        </p>
      </div>
      <div>
        <head>Data charting</head>
        <p>
          <s>Data was extracted independently in duplicate (SM and SDS).</s>
          <s id="1" type="Tabular data">Data extracted included: authors, publication year, country where study was conducted, economic evaluation type, study objective, data sources, outcomes reported, model type (CEA) or analytical technique (cost analyses), strategies compared (CEA), study perspective, time horizon, use of sensitivity analysis, discounting, use of a cost-effectiveness threshold (CET), and study findings.</s>
          <s>Since the objective of this Review was to summarize the existing literature, as well as to identify knowledge gaps in LD economic evidence, protocol registration, quality appraisal and meta-analyses were not conducted.</s>
        </p>
      </div>
      <div>
        <head>Summarizing results</head>
        <p>
          <s>A descriptive analysis was used to summarize studies included in the review.</s>
          <s>Themes for analysis include the type of economic evaluation conducted, countries/ regions where the study was conducted, types of outcomes reported, and the use of economic evaluation concepts recommended by the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.</s>
          <s>
            <ref target="#b14" type="bibr">[15]</ref> A descriptive analysis of the interventions compared in CEA economic evaluations, and the types of costs in costing economic evaluations were summarized.</s>
          <s>Costs were inflated to 2017 local currencies and standardized to US dollars (USD). Economic burden was expressed in cost per capita of the respective countries.</s>
        </p>
      </div>
      <div>
        <head>Results</head>
      </div>
      <div>
        <head>Literature search</head>
        <p>
          <s>Systematic searches resulted in a total of 923 records.</s>
          <s>After screening, a total of 21 studies were included in the final analysis <ref target="#fig_1" type="figure">(Fig 1)</ref> , 20 of which were peer-reviewed manuscripts and one report.</s>
          <s>Ten studies were categorized as CEA, <ref target="#b16" type="bibr">[17]</ref>
            <ref target="#b17" type="bibr">[18]</ref>
            <ref target="#b18" type="bibr">[19]</ref>
            <ref target="#b19" type="bibr">[20]</ref>
            <ref target="#b20" type="bibr">[21]</ref>
            <ref target="#b21" type="bibr">[22]</ref>
            <ref target="#b22" type="bibr">[23]</ref>
            <ref target="#b23" type="bibr">[24]</ref>
            <ref target="#b24" type="bibr">[25]</ref>
            <ref target="#b25" type="bibr">[26]</ref> and 11 were categorized as cost analyses.</s>
          <s>
            <ref target="#b26" type="bibr">[27,</ref>
            <ref target="#b27" type="bibr">28,</ref>
            <ref type="bibr">37,</ref>
            <ref target="#b28" type="bibr">[29]</ref>
            <ref target="#b29" type="bibr">[30]</ref>
            <ref target="#b30" type="bibr">[31]</ref>
            <ref target="#b31" type="bibr">[32]</ref>
            <ref target="#b32" type="bibr">[33]</ref>
            <ref target="#b33" type="bibr">[34]</ref>
            <ref target="#b34" type="bibr">[35]</ref>
            <ref target="#b35" type="bibr">[36]</ref> Economic evaluations associated with Lyme disease: A scoping review Descriptive analysis of economic evaluations <ref type="bibr">Fig 2 presents</ref> an overview of studies categorized by economic evaluation type, geographic region of origin, publication year and impact based on number of Google Scholar citations.</s>
          <s>The majority of included economic evaluations (n = 11, 52%) were published prior to 2003, with eight CEA <ref target="#b16" type="bibr">[17]</ref>
            <ref target="#b17" type="bibr">[18]</ref>
            <ref target="#b18" type="bibr">[19]</ref>
            <ref target="#b19" type="bibr">[20]</ref>
            <ref target="#b20" type="bibr">[21]</ref>
            <ref target="#b21" type="bibr">[22]</ref>
            <ref target="#b22" type="bibr">[23]</ref>
            <ref target="#b23" type="bibr">[24]</ref> and three cost analyses.</s>
          <s>
            <ref target="#b26" type="bibr">[27]</ref>
            <ref target="#b27" type="bibr">[28]</ref>
            <ref target="#b28" type="bibr">[29]</ref> From 2003 and onwards, there were 10 published economic evaluations: two CEA, <ref target="#b24" type="bibr">[25,</ref>
            <ref target="#b25" type="bibr">26]</ref> and eight cost analyses.</s>
          <s>
            <ref target="#b29" type="bibr">[30]</ref>
            <ref target="#b30" type="bibr">[31]</ref>
            <ref target="#b31" type="bibr">[32]</ref>
            <ref target="#b32" type="bibr">[33]</ref>
            <ref target="#b33" type="bibr">[34]</ref>
            <ref target="#b34" type="bibr">[35]</ref>
            <ref target="#b35" type="bibr">[36]</ref>
            <ref type="bibr">[37]</ref> All LD intervention CEAs were from NA countries, while cost analyses were published more frequently after 2003, and from European countries.</s>
          <s>The cost-effectiveness of antibiotic treatment strategies, <ref target="#b16" type="bibr">[17]</ref> and a diagnostic test cost analysis, <ref target="#b33" type="bibr">[34]</ref> were considered most impactful studies based on their number of Google Scholar citations.</s>
        </p>
      </div>
      <div>
        <head>Data source usage</head>
        <p>
          <s>Data sources used by the 21 economic evaluations, stratified by CEA and cost analysis, were summarized in <ref target="#fig_3" type="figure">Fig 3.</ref> Literature use was most common (n = 10, 48%), followed by insurance claims information (n = 8, 38%).</s>
          <s>CEAs mostly used existing literature, reports, and consulting experts, while cost analyses mostly used insurance claims or health provider data as well as questionnaire data to complete their economic evaluations.</s>
          <s>There were no economic evaluations that used health administrative data from a single payer health system.</s>
        </p>
      </div>
      <div>
        <head>Economic evaluations assessing cost-effectiveness</head>
        <p>
          <s>Study characteristics.</s>
          <s>Study design characteristics are summarized in <ref target="#tab_1" type="table">Table 1</ref> .</s>
          <s>Six CEA studies used a healthcare payer perspective, <ref target="#b16" type="bibr">[17]</ref>
            <ref target="#b17" type="bibr">[18]</ref>
            <ref target="#b18" type="bibr">[19]</ref>
            <ref target="#b19" type="bibr">[20]</ref>
            <ref target="#b23" type="bibr">24,</ref>
            <ref target="#b24" type="bibr">25]</ref> and four studies used a societal perspective, <ref target="#b20" type="bibr">[21]</ref>
            <ref target="#b21" type="bibr">[22]</ref>
            <ref target="#b22" type="bibr">[23]</ref>
            <ref target="#b25" type="bibr">26]</ref> of which three compared the cost-effectiveness of a vaccination program.</s>
          <s>
            <ref target="#b20" type="bibr">[21]</ref>
            <ref target="#b21" type="bibr">[22]</ref>
            <ref target="#b22" type="bibr">[23]</ref> One study also used a hospital perspective in the sensitivity analysis.</s>
          <s>
            <ref target="#b25" type="bibr">[26]</ref> The time horizon ranged between one-year and lifetime, with seven studies using a time horizon less than 10 years, <ref target="#b16" type="bibr">[17,</ref>
            <ref target="#b17" type="bibr">18,</ref>
            <ref target="#b21" type="bibr">[22]</ref>
            <ref target="#b22" type="bibr">[23]</ref>
            <ref target="#b23" type="bibr">[24]</ref>
            <ref target="#b24" type="bibr">[25]</ref>
            <ref target="#b25" type="bibr">[26]</ref> and only two using a lifetime horizon.</s>
          <s>
            <ref target="#b18" type="bibr">[19,</ref>
            <ref target="#b19" type="bibr">20]</ref> Ninety percent of CEAs completed a deterministic sensitivity analysis.</s>
          <s>
            <ref target="#b16" type="bibr">[17]</ref>
            <ref target="#b17" type="bibr">[18]</ref>
            <ref target="#b18" type="bibr">[19]</ref>
            <ref target="#b19" type="bibr">[20]</ref>
            <ref target="#b20" type="bibr">[21]</ref>
            <ref target="#b21" type="bibr">[22]</ref>
            <ref target="#b22" type="bibr">[23]</ref>
            <ref target="#b23" type="bibr">[24]</ref>
            <ref target="#b24" type="bibr">[25]</ref> Probabilistic sensitivity analyses were not presented.</s>
          <s>Discounting was used in six studies, <ref target="#b18" type="bibr">[19]</ref>
            <ref target="#b19" type="bibr">[20]</ref>
            <ref target="#b20" type="bibr">[21]</ref>
            <ref target="#b21" type="bibr">[22]</ref>
            <ref target="#b22" type="bibr">[23]</ref>
            <ref target="#b23" type="bibr">[24]</ref> where rates varied between 3% and 5% for base-case analyses, and between 0% (i.e.</s>
          <s>no discounting) and 10% in sensitivity analyses.</s>
        </p>
        <p>
          <s>Model type and interventions assessed.</s>
          <s>Seven CEAs reported an expected cost-effectiveness outcome using decision tree analysis <ref target="#b16" type="bibr">[17,</ref>
            <ref target="#b17" type="bibr">18,</ref>
            <ref target="#b19" type="bibr">[20]</ref>
            <ref target="#b20" type="bibr">[21]</ref>
            <ref target="#b21" type="bibr">[22]</ref>
            <ref target="#b24" type="bibr">25,</ref>
            <ref target="#b25" type="bibr">26]</ref> ;three CEAs used a Markov state-transition model.</s>
          <s>
            <ref target="#b18" type="bibr">[19,</ref>
            <ref target="#b22" type="bibr">23,</ref>
            <ref target="#b23" type="bibr">24]</ref> .</s>
          <s>Four studies assessed the cost-effectiveness of vaccination.</s>
          <s>
            <ref target="#b20" type="bibr">[21]</ref>
            <ref target="#b21" type="bibr">[22]</ref>
            <ref target="#b22" type="bibr">[23]</ref>
            <ref target="#b23" type="bibr">[24]</ref> Five CEAs assessed antibiotic cost-effectiveness: three studies compared treatment algorithms for early and late disseminated sequelae, <ref target="#b16" type="bibr">[17,</ref>
            <ref target="#b18" type="bibr">19,</ref>
            <ref target="#b19" type="bibr">20</ref> ] one compared treatment algorithms for early localized LD, <ref target="#b24" type="bibr">[25]</ref> and one assessed cost-effectiveness of intravenous ceftriaxone in patients who lacked classical clinical manifestations.</s>
          <s>
            <ref target="#b17" type="bibr">[18]</ref> Outcomes.</s>
          <s>Cost, health, and cost-effectiveness outcomes reported are summarized in <ref target="#tab_2" type="table">Table 2</ref> .</s>
          <s>Types of direct costs (healthcare costs) incorporated into models included: laboratory diagnostics, physician services, hospital care, medication and associated-adverse events (e.g.</s>
          <s>antibiotic treatment), sequelae, vaccination (e.g.</s>
          <s>administration, time, travel), and cost per LD case.</s>
          <s>Indirect costs included productivity loss.</s>
        </p>
        <p>
          <s>Health outcomes chosen for CEAs included: the number of major and minor complications (sequelae), number of therapy-related adverse events, number of LD cases averted, life expectancy, QALYs, and mortality.</s>
          <s>One study used test sensitivity and specificity outcomes.</s>
          <s>
            <ref target="#b25" type="bibr">[26]</ref> Incremental cost-effectiveness ratios (ICERs) reported were: cost per additional major complications prevented, cost per late LD case prevented, cost per QALY, and cost per LD case averted.</s>
          <s>One study did not conclude a cost-effectiveness ratio outcome.</s>
          <s>
            <ref target="#b25" type="bibr">[26]</ref>
          </s>
        </p>
      </div>
      <div>
        <head>Study findings</head>
        <p>
          <s>Conclusions from all CEA are summarized in <ref target="#tab_2" type="table">Table 2</ref> .</s>
          <s>All ICERs were inflated and standardized to 2017 USD per QALY.</s>
          <s>The ICER for vaccination programs are summarized in <ref type="table">Table 3</ref> and ranged between 7,024 USD (probability of LD infection of 0.5%, <ref target="#b20" type="bibr">[21]</ref> ) and 2.36M USD (probability of LD infection of 0.0067%, <ref target="#b23" type="bibr">[24]</ref> ) per LD case averted.</s>
          <s>Studies reporting the ICER Economic evaluations associated with Lyme disease: A scoping review in USD per QALY reported results between 93,619 (probability of infection of 1%, <ref target="#b22" type="bibr">[23]</ref> ) and 5.17M (probability of infection of 0.0046%, <ref target="#b21" type="bibr">[22]</ref> ) USD per QALY.</s>
          <s>The ICER varied depending on the probability of LD infection, probability of diagnosing early LD and vaccination costs.</s>
          <s>These three CEAs, all from societal perspectives, concluded that vaccination was likely economically favorable for endemic LD areas and not cost-effective for nation-wide administration.</s>
          <s>All four studies used a time horizon of 10 to 11 years, performed sensitivity analyses, and discounted at 3%.</s>
          <s>Economic evaluations associated with Lyme disease: A scoping review</s>
        </p>
      </div>
      <div>
        <head>Decision analysis</head>
        <p>
          <s>For myalgic symptom patients, the "no testing-no treatment" strategy was most economically attractive.</s>
          <s>For patients with EM-resembling rash, "Treat All" was the most cost-effective strategy.</s>
          <s>For patients with oligoarticular arthritis, the "two-step testing" was most economically attractive.</s>
          <s>Empirical treatment is most attractive when the annual incidence of new infection or pretest probability of LD was high.</s>
          <s>In 1992, Majid et al. concluded that empirical antibiotic treatment of patients with tick bites was cost-effective when the probability of infection was 0.036 or higher.</s>
          <s>
            <ref target="#b16" type="bibr">[17]</ref> Subsequent studies by Lightfoot et al., Nichols et al., and Lantos et al., also reported that an empirical antibiotic approach is cost-effective and preferred for patients with a positive Lyme antibody titer, if the pretest probability for LD is high, and for patients in regions endemic for LD.</s>
          <s>
            <ref target="#b17" type="bibr">[18,</ref>
            <ref target="#b19" type="bibr">20,</ref>
            <ref target="#b24" type="bibr">25]</ref> The study by Eckman et al. assessed the cost-effectiveness of oral antibiotic treatment using 100 mg of doxycycline compared to an intravenous administration of 2 g of ceftriaxone.</s>
          <s>This study concluded that oral doxycycline was dominant (cost savings and provided an additional 0.1 QALY) in both early LD and Lyme arthritis patients.</s>
          <s>
            <ref target="#b18" type="bibr">[19]</ref> Economic evaluations associated with Lyme disease: A scoping review</s>
        </p>
      </div>
      <div>
        <head>Economic evaluations assessing LD-associated costs</head>
        <p>
          <s>Study characteristics.</s>
          <s>Seven studies assessed the economic burden of LD using total healthcare costs, <ref target="#b27" type="bibr">[28]</ref>
            <ref target="#b28" type="bibr">[29]</ref>
            <ref target="#b29" type="bibr">[30]</ref>
            <ref target="#b30" type="bibr">[31]</ref>
            <ref target="#b34" type="bibr">35</ref> -37] three studies included diagnostic testing costs only, <ref target="#b26" type="bibr">[27,</ref>
            <ref target="#b31" type="bibr">32,</ref>
            <ref target="#b33" type="bibr">34]</ref> and one study included Lyme cardiac treatment costs only.</s>
          <s>
            <ref target="#b32" type="bibr">[33]</ref> Five studies used a healthcare payer perspective, <ref target="#b26" type="bibr">[27,</ref>
            <ref target="#b31" type="bibr">[32]</ref>
            <ref target="#b32" type="bibr">[33]</ref>
            <ref target="#b33" type="bibr">[34]</ref>
            <ref target="#b34" type="bibr">[35]</ref> six studies used a societal perspective, <ref target="#b27" type="bibr">[28]</ref>
            <ref target="#b28" type="bibr">[29]</ref>
            <ref target="#b29" type="bibr">[30]</ref>
            <ref target="#b30" type="bibr">[31]</ref>
            <ref target="#b35" type="bibr">36,</ref>
            <ref type="bibr">37]</ref> and two studies used a third-party payer perspective.</s>
          <s>
            <ref target="#b27" type="bibr">[28,</ref>
            <ref target="#b35" type="bibr">36]</ref> Approximately 91% (10 of 11) of cost analyses used a time horizon between 0 and 5 years.</s>
          <s>
            <ref target="#b26" type="bibr">[27]</ref>
            <ref target="#b27" type="bibr">[28]</ref>
            <ref target="#b28" type="bibr">[29]</ref>
            <ref target="#b29" type="bibr">[30]</ref>
            <ref target="#b30" type="bibr">[31]</ref>
            <ref target="#b31" type="bibr">[32]</ref>
            <ref target="#b32" type="bibr">[33]</ref>
            <ref target="#b33" type="bibr">[34]</ref>
            <ref target="#b34" type="bibr">[35]</ref>
            <ref target="#b35" type="bibr">[36]</ref> Only four studies completed any form of sensitivity analysis, <ref target="#b28" type="bibr">[29,</ref>
            <ref target="#b32" type="bibr">33,</ref>
            <ref target="#b34" type="bibr">35,</ref>
            <ref type="bibr">37]</ref> and two studies used discounting with rates between 3 and 4%.</s>
          <s>
            <ref target="#b27" type="bibr">[28,</ref>
            <ref type="bibr">37]</ref> Outcomes.</s>
          <s>Outcomes reported are summarized in <ref target="#tab_5" type="table">Table 4</ref> .</s>
          <s>Cost analyses focusing on overall healthcare costs included direct medical costs: outpatient visits and related healthcare utilization, hospitalizations, emergency room visits, home health care, prescription medication (antibiotic treatment), cost of subsequent manifestations (major or minor sequelae), consultations, laboratory costs, and treatment side effects.</s>
          <s>Diagnostic cost analyses only included serologic test costs and laboratory costs.</s>
        </p>
        <p>
          <s>Indirect costs that were incorporated for societal perspectives included: out-of-pocket drug costs, caregiving, travel, work loss, restricted-activity days at home, and loss of healthy time from sequelae.</s>
          <s>The study by Joss et al. incorporated the cost in the management of patients (e.g.</s>
          <s>consultations and screening test costs) found not to have evidence of the disease to evaluate non-confirmed LD patient burden from a societal perspective.</s>
          <s>
            <ref target="#b28" type="bibr">[29]</ref> Two studies used a human capital approach, <ref target="#b29" type="bibr">[30,</ref>
            <ref target="#b35" type="bibr">36]</ref> one study used friction cost methods, <ref type="bibr">[37]</ref> and three studies used secondary data to estimate indirect costs.</s>
          <s>
            <ref target="#b27" type="bibr">[28,</ref>
            <ref target="#b28" type="bibr">29,</ref>
            <ref target="#b30" type="bibr">31]</ref> Study findings.</s>
          <s>Three diagnostic cost analyses were included in this review <ref target="#tab_5" type="table">(Table 4)</ref> .</s>
          <s>Reported costs are standardized to 2017 USD currency using its respective inflation.</s>
          <s>The first US study by Strickland et al. concluded that 30,000 tests for LD were performed annually on Maryland residents, totalling direct medical costs of over 3.23M USD.</s>
          <s>
            <ref target="#b26" type="bibr">[27]</ref> More recently, Hinckley et al. concluded that 3.4 million LD tests were conducted by the seven laboratories involved in their study (from four endemic states: Connecticut, Maryland, Minnesota and New York), at an estimated national cost of 566M USD.</s>
          <s>
            <ref target="#b33" type="bibr">[34]</ref> Both studies concluded that diagnosis costs are a concern and should be included in the public health burden of LD.</s>
          <s>In Europe, a study by Muller et al. concluded that the overall expected cost of diagnostic testing and treatment was estimated at 67.93M USD in Germany, and suggested a high amount of potentially inappropriate healthcare services utilized for patients with a suspected or confirmed diagnosis of Lyme borreliosis.</s>
          <s>
            <ref target="#b31" type="bibr">[32]</ref> Overall, there were six cost analyses that assessed the economic burden of LD from a societal perspective: four from Europe, and two from the US <ref target="#tab_5" type="table">(Table 4)</ref> From a societal perspective, the total annual national economic burden of LD in Scotland was estimated to be £543,678 (£331,000, range £47,000-615,000, Sterling Pound 1999).</s>
          <s>An additional annual cost of £125,000-£156,513 (£76,000 -£95,000, Sterling Pound 1999) was spent for patients with a concern and no certainty of contracting LD.</s>
          <s>These costs were not included in the national estimate.</s>
          <s>From a societal perspective, the national economic burden of NB-related healthcare for Sweden over 5 years was estimated to be 598,119 EUR (500,000 EUR, EUR 2005) for the entire study group 3,948 EUR per patient (3,300 EUR), and the cost of social benefits was estimated to be 160,296 EUR (134,000 EUR), which is approximately 2,393 EUR (2,000 EUR) per patient.</s>
          <s>The study concluded that earlier diagnosis of borreliosis would result in reduced human suffering and in economic gain.</s>
        </p>
        <p>
          <s>Muller et al.; 2011 <ref target="#b31" type="bibr">[32]</ref> Germany Diagnostic; Healthcare payer</s>
        </p>
      </div>
      <div>
        <head n="1.">Costs: diagnostic testing, laboratory costs, treatment (separately)</head>
        <p>
          <s>In Germany, the overall expected burden from diagnostics was estimated at 57.0M EUR (51.2M</s>
          <s>EUR, EUR 2008) using diagnostic claims code data.</s>
          <s>The study's conclusion suggested a high amount of potentially inappropriate healthcare services in patients with a suspected or confirmed diagnosis of LB.</s>
        </p>
      </div>
      <div>
        <head>Discussion</head>
        <p>
          <s>We summarized a total of 21 economic evaluations (10 CEA and 11 cost analyses) related to LD.</s>
          <s>The majority of CEA studies were conducted prior to 2003, which was related to the previously available LD human vaccine.</s>
          <s>
            <ref target="#b8" type="bibr">[9]</ref> Since the vaccine was withdrawn, there has been no novel intervention strategies for LD and subsequently minimal interest in CEA studies after 2003.</s>
          <s>Although this vaccine was withdrawn for reasons other than cost-effectiveness, <ref target="#b8" type="bibr">[9]</ref> all four LD vaccination CEAs concluded that universal vaccination in the US was likely not costeffective.</s>
          <s>We included seven cost analyses focused on overall healthcare costs, three studies focused on diagnostic testing and one cost analysis focused on Lyme cardiac treatment.</s>
          <s>A common theme of the diagnostic cost analyses was the burden of inappropriate and over-usage of LD diagnostic testing in the US and Germany.</s>
          <s>While diagnostic economic evaluations specifically looking at costs are appreciated, it would be difficult for decision-makers to use this evidence in the absence of overall healthcare burden.</s>
          <s>Of the seven cost analyses assessing burden through total healthcare costs, three European studies concluded that further research and priority should be placed on preventive interventions for LD.</s>
          <s>Based on the most recent study by Zhang et al, the inflated annual economic impact for LD in the US was 292M USD.</s>
          <s>While this does not come close to the burden of influenza, cancer or chronic conditions (e.g.</s>
          <s>diabetes, obesity), it falls in the same magnitude of other high-profile vector-borne diseases in the US such as West Nile virus (778M USD over 13 years), <ref target="#b36" type="bibr">[38]</ref> and Zika virus (500M USD annual assuming a 0.3% attack rate across six prominent states).</s>
          <s>
            <ref target="#b37" type="bibr">[39]</ref> Overall, the economic burden of LD could be considered significant to the US and other developed countries to justify further research efforts in LD control and management.</s>
        </p>
        <p>
          <s>There are limitations to this review, as resource constraints limited our literature search to articles written in English, introducing possible language bias.</s>
          <s>As a result, there may be an underrepresentation of European studies, which should not be interpreted as a lack of interest or lower LD incidence rates in this region.</s>
          <s>We did not attempt to identify costs associated with LD avoidance (i.e.</s>
          <s>non-health related prevention) since we were interested in the economic burden of LD on the healthcare system and society.</s>
          <s>Per capita costs were presented by dividing nation-wide burden by the entire population.</s>
          <s>However, it should be acknowledged that not everyone from a specific country are susceptible to LD.</s>
          <s>As a result, our review may be underestimating the actual per capita costs in high incidence areas, and we advise against using these per capita estimates to describe LD burden.</s>
          <s>Lastly, since the goal of this scoping review was to characterize the literature, risk of bias assessment and quality appraisal were not completed.</s>
          <s>We propose quality appraisal of the literature be explored in a future systematic review.</s>
        </p>
        <p>
          <s>To our knowledge, this was the first study that systematically identified and characterized the economic evaluation literature for LD.</s>
          <s>In 1999 and 2002, reviews by Rouf et al. and Tella et al. identified costs, and cost-effectiveness studies in rheumatology, respectively.</s>
          <s>
            <ref target="#b38" type="bibr">[40,</ref>
            <ref target="#b39" type="bibr">41]</ref> However, both reviews identified limited LD studies and were not able to provide a comprehensive description of the burden of LD.</s>
          <s>The search strategy was comprehensively designed and adapted to four electronic databases to search NA and European literature.</s>
          <s>Given the amount of HTA and health economics organizations that release reports on vector-borne diseases, our search in the grey literature added to the comprehensiveness of this review.</s>
          <s>The timing of this review should be useful for health services and LD researchers alike aiming to understand the implications of this emerging infectious disease where it is estimated that 300,000 cases of LD are diagnosed annually in the US, <ref target="#b40" type="bibr">[42]</ref> with limited development of novel interventions.</s>
          <s>
            <ref target="#b41" type="bibr">[43]</ref> A recent scoping review from Canada by Greig et al. identified all LD literature (e.g.</s>
          <s>risk factors, surveillance, diagnostics) related to public health.</s>
          <s>In this review, they identified 32 hits related to economic burden of LD or cost-benefit of interventions, but do not specifically report on the results, trends or conclusions of the studies.</s>
          <s>
            <ref target="#b42" type="bibr">[44]</ref> In comparison, we included fewer studies since we excluded abstracts, editorials, secondary reviews, and economic evaluations not directly related to Lyme disease.</s>
          <s>Our review comes to a similar conclusion in that economic burden studies for LD are limited.</s>
        </p>
        <p>
          <s>Our review was able to highlight specific research gaps in the LD literature.</s>
          <s>Of the 11 cost analyses, six studies reported societal costs (i.e.</s>
          <s>productivity loss, indirect costs, non-medical costs) between 23 and 64% of total economic costs.</s>
          <s>However, many of these indirect costs were roughly estimated using friction cost or human capital approach methods.</s>
          <s>It is evident that while healthcare costs are significant for LD in various countries, the societal costs are equally as impactful for this disease and should be further studied.</s>
          <s>Our review also summarized the range of economic impact across various countries known to have increasing rates of LD, and countries that have not estimated the economic impact of this vector-borne disease while facing increasing LD cases (e.g.</s>
          <s>Canada) <ref target="#b43" type="bibr">[45]</ref> or historically have high LD incidence rates (e.g.</s>
          <s>Slovenia, Czech Republic).</s>
        </p>
        <p>
          <s>[46] Future efforts in identifying specific LD stages, indirect costs, or healthcare utilization that create the highest economic burden can be useful to support public health agenda in countries with this vector-borne disease.</s>
        </p>
        <p>
          <s>There was a high degree of heterogeneity in economic evaluation methods, data sources and outcomes reported.</s>
          <s>The cost/QALY gained outcome is typically used to express the costeffectiveness to health policy decision-makers, since it can be compared to commonly-used thresholds (e.g., $50,000/QALY, <ref target="#b44" type="bibr">[47]</ref> and 20,000 Sterling Pounds/QALY in the United Kingdom <ref target="#b45" type="bibr">[48]</ref> ).</s>
          <s>However, many studies reported cost-effectiveness in other units, limiting appropriate comparisons.</s>
          <s>We also noticed an array of LD health states, and health state utility values (HSUV) used.</s>
          <s>HSUVs for LD health states were mostly derived from expert clinical opinion, which could in turn be underestimating the QALYs and the cost-effectiveness of interventions.</s>
          <s>Furthermore, an individualized approach (e.g.</s>
          <s>individual-level microsimulation) may be more accurate in predicting cost-effectiveness of LD interventions, since unique baseline characteristics of patients (e.g.</s>
          <s>comorbidities and demographics) can affect disease progression and subsequently predicted lifetime outcomes.</s>
        </p>
        <p>
          <s>Only cost analyses from the US provided sequelae-attributable costs and case-attributable costs per patient.</s>
          <s>
            <ref target="#b34" type="bibr">[35]</ref> As big data and computing power evolve in health care, future studies can further investigate attributable healthcare costs using health administrative data to determine population-specific burden.</s>
          <s>Future health services research should thus consider the local context in generating evidence to support health decision makers given the regional differences in LD incidence, detection, symptoms, sequelae and healthcare systems.</s>
        </p>
      </div>
      <div>
        <head>Conclusions</head>
        <p>
          <s>This scoping review identified 21 economic evaluations for Lyme disease from North America and Europe.</s>
          <s>Similar to other vector-borne diseases, the burden of Lyme disease suggests an economic argument for further research.</s>
          <s>A greater understanding of the indirect costs of Lyme disease and cost-effectiveness of interventions in countries where the incidence rates of the disease are increasing, is warranted for guiding Lyme disease evidence-informed health policy decision making.</s>
        </p>
      </div>
      <div>
        <head>Supporting information</head>
      </div>
      <figure xml:id="fig_0">
        <head>[ 16 ]</head>
        <label>16</label>
        <figDesc>Results were stratified into pre- 2003 and post-2003 periods to explore any trends resulting from the withdrawal of human LD vaccine in February 2002. [9]</figDesc>
      </figure>
      <figure xml:id="fig_1">
        <head>Fig 1 .</head>
        <label>1</label>
        <figDesc>Fig 1. Literature search and study selection. https://doi.org/10.1371/journal.pone.0210280.g001</figDesc>
      </figure>
      <figure xml:id="fig_2">
        <head>Fig 2 .</head>
        <label>2</label>
        <figDesc>Fig 2. Bubble chart displaying studies included in review by study year, geographic region, and type of economic evaluation. Balloon size depicts the number of citations through Google Scholar. https://doi.org/10.1371/journal.pone.0210280.g002</figDesc>
      </figure>
      <figure xml:id="fig_3">
        <head>Fig 3 .</head>
        <label>3</label>
        <figDesc>Fig 3. Data sources used by LD cost-effectiveness analyses and cost analyses. � New Jersey Blue Cross-Blue Shield; Diversified Pharmaceutical Services; Delmarva Health Plan; Swedish Social Insurance; German DAK; IMS Health LifeLink Health Plan Claims; �� CDC LD Incidence Reports, Epidemiologic Reports, Lyme Disease Vaccine Study Group; ��� Scottish Health Service, Departments of Economy and Information Technology. https://doi.org/10.1371/journal.pone.0210280.g003</figDesc>
      </figure>
      <figure xml:id="fig_4">
        <head/>
        <label/>
        <figDesc>. Joss et al. reported an annual national economic burden of 735,550 USD (0.14 USD per capita, n = 5.40M) for Scotland,[29] while Henningsson et al. reported a national economic burden of 712,808 USD over 5 years in Sweden (0.07 USD per capita, n = 9.96M) for neuroborreliosis-related healthcare.[31] Further- more, Lohr et al. reported an annual national economic impact of over 40.88M USD in Ger- many (0.51 USD per capita, n = 80.59M),[36] and van den Wijngaard et al. reported an annual national cost of 23.12M USD for LB in the Netherlands (1.36 USD per capita, n = 17.08M). [37] In the US, cost analyses were completed sporadically from 1998 to 2015. A cost-of-illness study by Maes et al. reported an expected national expenditure of 3.93 billion USD over five years (2.41 USD per capita per year, n = 326.63M).[28] A healthcare utilization study by Zhang et al. reported direct medical costs of 4,273 USD and indirect costs of 7,484 USD per LD patient, totalling an estimated nationwide economic impact of 292M USD (0.89 USD per</figDesc>
      </figure>
      <figure xml:id="fig_5">
        <head/>
        <label/>
        <figDesc>Direct Medical Costs: LD diagnosis and treatment, physician visits, consultation, serology, procedure, therapy, hospitalization/ ER visits 1b. Indirect Medical Costs: extra prescription and non-prescription drug costs paid out of pockets 1c. Non-medical Costs: home or health aides, travel and caregiving 1d. Costs, productivity loss: patient reported time lost from work (intangible costs of pain and suffering were not incorporated). Additional direct medical costs and indirect medical costs were estimated at $4,273 ($2,970, USD 2000), and $7,484 ($5,202, USD 2000) respectively for early and or late stage LD patients. From a societal perspective, the annual national economic burden was estimated at $292M ($203M, USD 2000). Study concluded the need on further research on social behaviour and economic evaluations of LD prevention interventions.Direct Costs: physician visits to outpatient department, hospitalization, antibiotic treatment 1b. Indirect Costs: sickness benefit (temporary parental benefits) 2. Health Outcomes: recovery after antibiotic treatment (full or partial)</figDesc>
      </figure>
      <figure xml:id="fig_6">
        <head>S1</head>
        <label/>
        <figDesc>Text. Medline search strategy (on November 08, 2017). (DOCX) S1</figDesc>
      </figure>
      <figure type="table" validated="false" xml:id="tab_0">
        <head/>
        <label/>
        <figDesc>.88M USD in Germany (0.51 USD per capita, 80.59M), 23.12M USD in the Netherlands (1.36 USD per capita, 17.08M), and up to 786M USD in the US (2.41 USD per capita, 326.63M). PLOS ONE | https://doi.org/10.1371/journal.pone.</figDesc>
        <table>0210280 January 4, 2019 
1 / 17 

a1111111111 
a1111111111 
a1111111111 
a1111111111 
a1111111111 </table>
      </figure>
      <figure type="table" validated="false" xml:id="tab_1">
        <head>Table 1 .</head>
        <label>1</label>
        <figDesc>Economic evaluation study characteristics.Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Moldova, Monaco, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, Vatican City 2 Perspectives were classified based on the costs included by the authors if it was not explicitly stated; percentages may not add up to 100% in certain cases if studies examined multiple perspectives. CEA, Cost-effectiveness analysis; N/Ap, Not applicable https://doi.org/10.1371/journal.pone.0210280.t001</figDesc>
        <table>Study Characteristics, n (%) 
CEA (n = 10) 
Cost analysis (n = 11) 

Year of Study 

Pre-2003 
8 (80) 
3 (27) 

2003-2017 
2 (25) 
8 (73) 

Country where study conducted 

North American countries 
10 (100) 
3 (27) 

European countries 

1 

0 
8 (73) 

Number of strategies compared 

Two or less 
6 (60) 
N/Ap 

Three or more 
4 (40) 
N/Ap 

Type of CEA Model 

Decision analysis 
7 (70) 
N/Ap 

Markov cohort model 
3 (30) 
N/Ap 

Type of Costing Study 

Healthcare costs 
N/Ap 
7 (64) 

Diagnostic testing costs only 
N/Ap 
3 (27) 

Treatment costs only 
N/Ap 
1 (9) 

Number of different outcomes included 

Two or less 
1 (10) 
10 (91) 

Three or more 
9 (90) 
1 (9) 

Study Perspective 

2 

Healthcare payer 
6 (60) 
5 (45) 

Societal 
4 (40) 
6 (55) 

Other (hospital or third party payer) 
1 (10) 
2 (18) 

Time Horizon 

0-5 years 
4 (40) 
10 (91) 

5-10 years 
3 (30) 
-

&gt; 10 years but not lifetime 
1 (12) 
-

Lifetime 
2 (25) 
1 (9) 

Use of Sensitivity Analysis 
9 (90) 
4 (36) 

Use of Discounting 
6 (60) 
2 (18) 

1 </table>
      </figure>
      <figure type="table" validated="false" xml:id="tab_2">
        <head>Table 2 .</head>
        <label>2</label>
        <figDesc>Primary study characteristics and conclusions of cost-effectiveness analyses.Canada 1. Costs: Testing, therapy for each syndrome, treatment, minor/major side effects, sequelae 2. Utilities: Time Trade-off 3. Health Outcomes: Life expectancy, QALY, sequelae 4. ICER: USD per QALY</figDesc>
        <table>Author 
Country Outcomes 
Comparator Strategies 
Model 
Type 

Conclusions (Unadjusted) 

Magid 
et al. [17] 

USA 
1. Costs: lab tests, physician services, 
hospital care, and hospital medications 
2. Health Outcomes: Major and minor 
complications (sequelae), patients 
reactions to antibiotics 
3. ICER: USD per additional major 
complications prevented 

1. Treat all, Empirically treat all patients 
with 2 weeks of doxycycline 
2. Follow, Treat only patients in whom 
EM develops 
3. Test, Treat only patients with EM or a 
positive serologic test for LD one month 
after exposure 

Decision 
analysis 

Empirical treatment ("Treat All") of 
patients with tick bites was most cost-
effective when the probability of infection 
after a bite is � 0.036 or higher. If 
probability of infection &lt; 0.01, "Follow" 
is most cost-effective compared to other 
strategies. 

Lightfoot 
et al. [18] 

USA 
1. Costs: antibiotic treatment, side effects 
2. Health outcomes: side effects of 
ceftriaxone therapy, getting late LD 
3. ICER: USD per case of late LD 
prevented 

1. Empirical IV antibiotic treatment, of 
non-specifically symptomatically patient 
who has a positive Lyme antibody titer 
2. No antibiotic treatment 

Decision 
analysis 

Empirical treatment resulted in an ICER 
(USD 1993) of $86,221 per LD case 
prevented. For most patients with a 
positive Lyme antibody titer and non-
specific symptoms, the risks and costs of 
empirical parenteral antibiotic therapy 
exceed the benefits (i.e. not cost-effective) 

Eckman 
et al.[19] 

USA 
1. Costs: hospitalization for 
complications of antibiotic therapy, 
ambulatory visits, and treatment 
2. Health outcomes: Anaphylaxis, minor 
and major complications, quality of life 
3. ICER: USD per QALY 

1. Oral therapy with 100 mg of 
doxycycline, twice daily for three weeks 
(in patients with early LD) or four weeks 
(in those with Lyme arthritis) 
2. At-home IV administration of 
ceftriaxone, 2 grams once a day for two 
weeks (in patients with early LD) or four 
weeks (in those with Lyme arthritis) 

Markov 
cohort 
model 

When compared to IV ceftriaxone for 
treatment of early LD and Lyme arthritis, 
oral therapy of doxycycline was dominant 
(i.e. cost savings of $544 and $546, and 
health benefits of 0.1 QALY for both early 
LD and Lyme arthritis, respectively). 

Nichol 
et al.[20] 

1. No testing-no treatment 
2. Testing, with enzyme-linked 
immunosorbent assay (ELISA) followed 
by antibiotic treatment of patients with 
positive results 
3. Two-step testing, with ELISA 
followed by Western blot and antibiotic 
treatment for patients with positive 
results on either test 
4. Empirical antibiotic therapy 

</table>
      </figure>
      <figure type="table" validated="false" xml:id="tab_4">
        <head>Table 2 .Table 3 .</head>
        <label>23</label>
        <figDesc>(Continued)AE, Adverse events; CEA, Cost-effectiveness analysis; EE, Economic evaluation; EIA, Enzyme immunoassay test; ELISA, Enzyme-linked immunosorbent assay; EM, Erythema migrans; HRQoL, Health-related quality of life; ICER, Incremental cost-effectiveness ratio; IgG, Immunoglobulin G; IgM, Immunoglobulin M; IV, intravenous; LB, Lyme borreliosis; LD, Lyme disease; N/Ap, Not applicable; NR, Not reported; P (LD | EM), Probability of Lyme disease given erythema migrans rash; QALY, Quality-adjusted life years; SA, Sensitivity analysis; USA, United States of America; USD, United States dollar; WCS, whole cell sonicate https://doi.org/10.1371/journal.pone.0210280.t002Summary of standardized ICER for vaccination programs in the United States.ICER, Incremental cost-effectiveness ratio; LD, Lyme disease; QALY, Quality-adjusted life year; USD, United States Dollar https://doi.org/10.1371/journal.pone.0210280.t003</figDesc>
        <table>Author 
Country Outcomes 
Comparator Strategies 
Model 
Type 

Conclusions (Unadjusted) 

Hsia et al. 
[24] 

USA 
1. Costs: vaccine/booster and 
administration, antibiotics, adverse drug 
reactions, major and minor sequelae 
2. Health Outcomes: cases averted 
3. ICER: USD per case averted 

1. Vaccination 
2. No vaccination 

Markov 
cohort 
model 

At an LD incidence rate of 0.01, the ICER 
(USD 1999) was $9,900 per LD case 
averted. At average national incidence 
rate of 0.0067%, the ICER was $1.6M per 
case averted. Vaccination is not cost-
effective for universal use in the US; only 
for individuals who live endemic areas. 

Lantos 
et al. [25] 

USA 
1. Costs: antibiotic treatment, laboratory 
testing, disseminated LD, major adverse 
medication effects, sequelae, and serology 
2. Health outcomes: Cases averted per 
100,000 patients, Disseminated cases per 
100,000 patients, major AE per 100,000 
patients 
3. ICER: USD per patient, USD per case 
averted 

1. Treat All, all patients given a standard 
course of antibiotics intended to treat 
EM due to early LD 
2. Observe, treat only if disseminated LD 
developed 
3. Serology, patients are tested using 
standard two-tier serology (ELISA 
followed by WB) and antibiotics are 
given to those meeting criteria for 
seropositivity, while negative test 
patients are observed 

Decision 
analysis 

All strategies became more costly as the P 
(LD | EM) increased. In terms of costs per 
patients, "Treat All" was cost-effective 
compared to the other strategies when P 
(LD | EM). &gt; 0.0061. In costs per averted 
disseminated LD, "Treat All" was always 
cost-effective when compared to the 
"Serology" strategy regardless of P (LD | 
EM). 

Wormser 
et al. [26] 

USA 
1. Costs: Median direct costs 
(undiscounted) of LD serological tests, 
and median net costs (reimbursement 
reflect median Centers for Medicare and 
Medicaid Services for 2012) 
2. Outcomes: Test sensitivity and 
specificity 
3. ICER: None 

1-2. The C6 Lyme ELISA kit plus either 
of two WCS ELISAs 
3-4. The immunoblot assays used with 
the Lyme IgG and IgM immunoblot kits 
from MarDx/Trinity Biotech 

Decision 
analysis 

The WCS ELISA followed by the C6 
ELISA was a dominant testing strategy 
(i.e. cost saving by 27.1% to 44%, and 
more sensitive). 

</table>
      </figure>
      <figure type="table" validated="true" xml:id="tab_5">
        <head>Table 4 .</head>
        <label>4</label>
        <figDesc>Primary study characteristics and conclusions of cost analyses.</figDesc>
        <table>Authors; Year 
Country 
Cost Type; 
Perspective 

Outcomes 
Conclusions (Unadjusted Costs) 

Strickland et al.; 
1997 [27] 

USA 
Diagnostic; 
Healthcare 
payer 

1. Costs: serologic tests (EIA and Western Blot) 
Physicians in Maryland often used EIAs to follow 
patients after treatment, an inappropriate practice that 
increases the overall cost of testing for LD. A total of 
30,000 tests for LD were performed annually in 
Maryland adding an annual burden of $3.23 million ($2 
million, USD 1995) in direct medical costs. 

Maes et al.; 1998 
[28] 

USA 
Healthcare; 
Societal 

1. Direct Costs: Direct medical costs (outpatient visits, 
hospitalizations, emergency room visits, home health 
care, and prescription medication, cost per episode, 
cost of chronic manifestations); 
1b. Indirect Costs: work loss, restricted-activity days 
at home) 
2. Health Outcomes: Stage II and III sequelae 
prevented 

Using an annual mean incidence of 4.73 cases of Lyme 
disease per 100,000 population, the model extrapolated 
expenditures from US endemic areas and yielded an 
expected national expenditure of $3.93 billion ($2.5 
billion, USD 1996) over 5 years for therapeutic 
interventions to prevent 55,626 cases of Lyme disease 
sequelae. This study suggested the need to develop 
vaccination strategies for specific target groups. 

Joss et al.; 2002 
[29] 

Scotland 
Healthcare; 
Societal 

1. Direct Costs: Direct costs of consultation; 
laboratory costs; antibiotic treatment, including a 
percentage increment for possible major or minor 
side-effects; cardiac, neurologic or musculoskeletal/ 
arthritic sequelae); 
1b. Indirect Costs: loss of healthy time, and from 
sequelae 
1c. Costs, probable cases: consultation and screening 
tests costs 

</table>
      </figure>
      <figure type="table" validated="false" xml:id="tab_7">
        <head>Table 4 .</head>
        <label>4</label>
        <figDesc>EUR 2014). Healthcare cost and production loss each constituted 48% of the total cost at 9.33M (9.3M) EUR and 9.23M (9.2M) EUR, respectively), while patient costs contributed 4% at 0.8M (0.8M) EUR. LB leads to a substantial societal cost. Further research should therefore focus on additional preventive interventions.</figDesc>
        <table>(Continued) 

Authors; Year 
Country 
Cost Type; 
Perspective 

Outcomes 
Conclusions (Unadjusted Costs) 

Hinckley et al.; 
2014 [34] 

USA 
Diagnostic; 
Healthcare 
payer 

1. Costs: Amount charged by commercial laboratories 
that is ultimately paid by insurance companies, 
Medicare/Medicaid, the patient, and/or the ordering 
medical center (e.g. hospitals, clinics) 

Approximately 3.4M LD diagnostic tests were 
conducted by participating laboratories in 2008, at an 
estimated cost of $556M ($492M, USD 2008). LD testing 
was common and costly, even when testing was in 
accordance with diagnostic recommendations. It is 
important to consider clinical and exposure history in 
conjunction with diagnostic evidence. 

Adrion et al.; 2015 
[35] 

USA 
Healthcare; 
Healthcare 
payer 

1. Costs: total inpatient, total pharmacy, total 
outpatient, outpatient anesthesiology, outpatient 
evaluation and management, outpatient medicine, 
outpatient pathology laboratory, outpatient radiology, 
outpatient surgery, and all other outpatient costs 
2. Utilization: outpatient management and evaluation 
visits, and emergency department visits 

LD was associated with an increase of $3,048 ($2,968, 
95% CI: 2,807-3,128, USD 2015) health care costs over a 
12-month period. PTLDS-related diagnosis was 
associated with an increase of $3,946 ($3,798, 95% CI: 
3,542-4,055) health care costs over a 12-month period, 
relative to those with no PTLDS related diagnoses. 
Using estimated costs, annual total medical costs 
attributable to LD and PTLDS could be between $740M 
and $1.35B ($712M and $1.3B) annually in the US. 

Lohr et al.; 2015 
[36] 

Germany 
Healthcare; 
Societal 

1. Direct Costs: medical hospitalization costs 
1b. Indirect Costs: resulting from loss of productivity 
(human capital approach) 

From a societal perspective, the annual national 
economic burden of LD in Germany was 34.3M EUR 
(30.8M EUR, EUR 2008) where the breakdown was 
25.6M (23M) EUR for direct medical costs and 7.8M 
(7M) EUR for indirect costs. Study results were 
considered to be underestimated. 

van den Wijngaard 
et al.; 2017 [37] 

Netherlands Healthcare; 
Societal 

1. Direct Costs: GP consultations, specialist 
consultations, hospitalization, prescribed medications 
and formal home care 
1b. Indirect costs, out of pocket: informal care, self-
paid household assistance, caregiving, OTC 
medication excluded 
1c. Indirect Costs, production loss: friction cost 
method and friction period of 12.1 weeks for work 
absenteeism 
2. Health Outcomes: no infection, asymptomatic 
infection, EM, disseminated LB, Lyme-related 
persisting symptoms 

From a societal perspective, the annual national 
economic burden of LD in the Netherlands was 
estimated at 19.4M EUR (19.3M EUR, 95% CI 15.6-
23.4, </table>
      </figure>
      <figure type="table" validated="false" xml:id="tab_8">
        <head>Table .</head>
        <label>.</label>
        <figDesc>PRISMA checklist. (DOC)</figDesc>
        <table/>
      </figure>
      <note place="foot">PLOS ONE | https://doi.org/10.1371/journal.pone.0210280 January 4, 2019</note>
      <note place="foot">PLOS ONE | https://doi.org/10.1371/journal.pone.0210280 January 4, 2019 6 / 17</note>
    </body>
    <back>
      <div type="acknowledgement">
        <div>
          <head>Acknowledgments</head>
          <p>
            <s>The authors wish to acknowledge librarian Vincci Lui for her guidance on the best practices of literature search strategy development.</s>
          </p>
        </div>
        <div>
          <head>Methodology: Stephen Mac.</head>
          <p>
            <s>Supervision: Beate Sander.</s>
          </p>
        </div>
        <div>
          <head>Visualization:</head>
          <p>
            <s>Stephen Mac, Sara R. da Silva.</s>
          </p>
        </div>
        <div>
          <head>Writing -original draft:</head>
          <p>
            <s>Stephen Mac.</s>
          </p>
        </div>
        <div>
          <head>Writing -review &amp; editing:</head>
          <p>
            <s>Stephen Mac, Sara R. da Silva, Beate Sander.</s>
          </p>
        </div>
      </div>
      <div type="annex">
        <div>
          <head>Author Contributions</head>
          <p>
            <s>Conceptualization: Stephen Mac, Beate Sander.</s>
          </p>
        </div>
        <div>
          <head>Data curation:</head>
          <p>
            <s>Stephen Mac, Sara R. da Silva.</s>
          </p>
        </div>
        <div>
          <head>Formal analysis:</head>
          <p>
            <s>Stephen Mac, Sara R. da Silva.</s>
          </p>
          <p>
            <s>Funding acquisition: Beate Sander.</s>
          </p>
        </div>
        <div>
          <head>Investigation:</head>
          <p>
            <s>Stephen Mac, Sara R. da Silva.</s>
          </p>
        </div>
      </div>
      <div type="references">
        <listBibl>
          <biblStruct xml:id="b0">
            <analytic>
              <title level="a" type="main">Epidemiology of Lyme Disease</title>
              <author>
                <persName>
                  <forename type="first">P</forename>
                  <forename type="middle">S</forename>
                  <surname>Mead</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Infect Dis Clin North Am</title>
              <imprint>
                <biblScope unit="volume">29</biblScope>
                <biblScope from="187" to="210" unit="page"/>
                <date type="published" when="2015"/>
                <publisher>Elsevier Inc</publisher>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b1">
            <analytic>
              <title level="a" type="main">An estimate of Lyme borreliosis incidence in Western Europe</title>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <forename type="middle">A</forename>
                  <surname>Sykes</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">P</forename>
                  <surname>Makiello</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">J Public Health (Bangkok)</title>
              <imprint>
                <biblScope unit="volume">39</biblScope>
                <biblScope from="74" to="81" unit="page"/>
                <date type="published" when="2016"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b2">
            <analytic>
              <title/>
            </analytic>
            <monogr>
              <title level="j">Centers for Disease Control and Prevention. Data and Statistics | Lyme Disease | CDC</title>
              <imprint>
                <biblScope unit="page">29</biblScope>
                <date type="published" when="2017-05"/>
              </imprint>
            </monogr>
            <note>Internet</note>
          </biblStruct>
          <biblStruct xml:id="b3">
            <monogr>
              <title level="m" type="main">European Centre for Disease Prevention and Control. Lyme Borreliosis in Europe</title>
              <imprint/>
            </monogr>
            <note>Internet</note>
          </biblStruct>
          <biblStruct xml:id="b4">
            <analytic>
              <title/>
            </analytic>
            <monogr>
              <title level="j">World Health Organization. WHO | World Health Day</title>
              <imprint>
                <biblScope unit="issue">7</biblScope>
                <date type="published" when="2014-04-05"/>
              </imprint>
            </monogr>
            <note>Internet. cited</note>
          </biblStruct>
          <biblStruct xml:id="b5">
            <analytic>
              <title level="a" type="main">Lyme Disease in Canada: An Update on the Epidemiology</title>
              <author>
                <persName>
                  <forename type="first">S</forename>
                  <surname>Habegger</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Natl Collab Cent Infect Dis Purple Pap</title>
              <imprint>
                <biblScope unit="volume">43</biblScope>
                <date type="published" when="2014"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b6">
            <monogr>
              <title level="m" type="main">Federal Framework on Lyme Disease Act (S.C. 2014, c. 37)</title>
              <author>
                <persName>
                  <forename type="first">Canada</forename>
                  <surname>Government Of</surname>
                </persName>
              </author>
              <ptr target="http://laws-lois.justice.gc.ca/eng/acts/F-7.35/FullText.html"/>
              <imprint>
                <date type="published" when="2016-11"/>
                <biblScope unit="page">12</biblScope>
              </imprint>
            </monogr>
            <note>Internet</note>
          </biblStruct>
          <biblStruct xml:id="b7">
            <analytic>
              <title level="a" type="main">Practice Guidelines for the Treatment of Lyme Disease</title>
              <author>
                <persName>
                  <forename type="first">G</forename>
                  <forename type="middle">P</forename>
                  <surname>Wormser</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <forename type="middle">B</forename>
                  <surname>Nadelman</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <forename type="middle">J</forename>
                  <surname>Dattwyler</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <forename type="middle">T</forename>
                  <surname>Dennis</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">E</forename>
                  <forename type="middle">D</forename>
                  <surname>Shapiro</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">C</forename>
                  <surname>Steere</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Clin Infect Dis</title>
              <imprint>
                <biblScope unit="volume">31</biblScope>
                <biblScope from="1" to="14" unit="page"/>
                <date type="published" when="2000"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b8">
            <analytic>
              <title level="a" type="main">Vaccines against Lyme disease: What happened and what lessons can we learn?</title>
              <author>
                <persName>
                  <forename type="first">G</forename>
                  <forename type="middle">A</forename>
                  <surname>Poland</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Clin Infect Dis. United States</title>
              <imprint>
                <biblScope unit="volume">52</biblScope>
                <biblScope from="253" to="258" unit="page"/>
                <date type="published" when="2011"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b9">
            <analytic>
              <title level="a" type="main">Scoping studies: Towards a methodological framework</title>
              <author>
                <persName>
                  <forename type="first">H</forename>
                  <surname>Arksey</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">O</forename>
                  <surname>Malley</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">L</forename>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Int J Soc Res Methodol Theory Pract</title>
              <imprint>
                <biblScope unit="volume">8</biblScope>
                <biblScope from="19" to="32" unit="page"/>
                <date type="published" when="2005"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b10">
            <analytic>
              <title level="a" type="main">The Joanna Briggs Institute Reviewers' Manual</title>
              <author>
                <persName>
                  <forename type="first">The Joanna Briggs</forename>
                  <surname>Institute</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Methodology for JBI Scoping Reviews. South Australia</title>
              <imprint>
                <date type="published" when="2015"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b11">
            <analytic>
              <title level="a" type="main">Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement</title>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <surname>Moher</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <surname>Liberati</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <surname>Tetzlaff</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <forename type="middle">G</forename>
                  <surname>Altman</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <surname>Altman</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">G</forename>
                  <surname>Antes</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">PLoS Med</title>
              <imprint>
                <biblScope unit="volume">6</biblScope>
                <biblScope from="1" to="6" unit="page"/>
                <date type="published" when="2009"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b12">
            <monogr>
              <title level="m" type="main">Matters: a practical tool for searching health-related grey literature | CADTH.ca</title>
              <author>
                <persName>
                  <surname>Cadth</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <surname>Grey</surname>
                </persName>
              </author>
              <ptr target="https://www.cadth.ca/resources/finding-evidence/grey-matters"/>
              <imprint>
                <date type="published" when="2017-10"/>
                <biblScope unit="page">14</biblScope>
              </imprint>
            </monogr>
            <note>Internet</note>
          </biblStruct>
          <biblStruct xml:id="b13">
            <monogr>
              <title level="m" type="main">HTA 101: Introduction to Health Technology Assessment</title>
              <author>
                <persName>
                  <forename type="first">C</forename>
                  <forename type="middle">S</forename>
                  <surname>Goodman</surname>
                </persName>
              </author>
              <imprint>
                <date type="published" when="2014"/>
                <pubPlace>Bethesda, MD</pubPlace>
              </imprint>
              <respStmt>
                <orgName>National Library of Medicine</orgName>
              </respStmt>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b14">
            <monogr>
              <title level="m" type="main">Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and elaboration: A report of the ISPOR Health Economic Evaluations Publication Guidelines Task Force. Value Heal</title>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <surname>Husereau</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <surname>Drummond</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">S</forename>
                  <surname>Petrou</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">C</forename>
                  <surname>Carswell</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <surname>Moher</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <surname>Greenberg</surname>
                </persName>
              </author>
              <imprint>
                <date type="published" when="2013"/>
                <biblScope unit="volume">16</biblScope>
                <biblScope from="231" to="250" unit="page"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b15">
            <monogr>
              <title level="m" type="main">Central Intelligence Agency. The World Factbook</title>
              <imprint>
                <date type="published" when="2017-05"/>
                <biblScope unit="page">11</biblScope>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b16">
            <analytic>
              <title level="a" type="main">Prevention of Lyme disease after tick bites. A cost-effectiveness analysis</title>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <surname>Magid</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">B</forename>
                  <surname>Schwartz</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <surname>Craft</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">S</forename>
                  <surname>Schwartz</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <forename type="middle">M</forename>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">B</forename>
                  <forename type="middle">S</forename>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">N Engl J Med. United States</title>
              <imprint>
                <biblScope unit="volume">327</biblScope>
                <biblScope from="534" to="541" unit="page"/>
                <date type="published" when="1992"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b17">
            <analytic>
              <title level="a" type="main">Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease: A cost-effectiveness analysis</title>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <forename type="middle">W</forename>
                  <surname>Lightfoot</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">B</forename>
                  <forename type="middle">J</forename>
                  <surname>Luft</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <forename type="middle">W</forename>
                  <surname>Rahn</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">C</forename>
                  <surname>Steere</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">L</forename>
                  <forename type="middle">H</forename>
                  <surname>Sigal</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <forename type="middle">C</forename>
                  <surname>Zoschke</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Ann Intern Med</title>
              <imprint>
                <biblScope unit="volume">119</biblScope>
                <biblScope unit="page">8357117</biblScope>
                <date type="published" when="1993"/>
                <publisher>PMID</publisher>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b18">
            <analytic>
              <title level="a" type="main">Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis</title>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <forename type="middle">H</forename>
                  <surname>Eckman</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">C</forename>
                  <surname>Steere</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <forename type="middle">A</forename>
                  <surname>Kalish</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">S</forename>
                  <forename type="middle">G</forename>
                  <surname>Pauker</surname>
                </persName>
              </author>
              <idno type="doi">10.1056/NEJM199707313370525</idno>
              <ptr target="https://doi.org/10.1056/NEJM199707313370525PMID"/>
            </analytic>
            <monogr>
              <title level="j">N Engl J Med</title>
              <imprint>
                <biblScope unit="volume">337</biblScope>
                <biblScope unit="page">9233874</biblScope>
                <date type="published" when="1997"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b19">
            <analytic>
              <title level="a" type="main">Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis</title>
              <author>
                <persName>
                  <forename type="first">G</forename>
                  <surname>Nichol</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <forename type="middle">T</forename>
                  <surname>Dennis</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">C</forename>
                  <surname>Steere</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <surname>Lightfoot</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">G</forename>
                  <surname>Wells</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">B</forename>
                  <surname>Shea</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Ann Intern Med</title>
              <imprint>
                <biblScope unit="volume">128</biblScope>
                <biblScope unit="page">9424980</biblScope>
                <date type="published" when="1998"/>
                <publisher>PMID</publisher>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b20">
            <analytic>
              <title level="a" type="main">The cost effectiveness of vaccinating against Lyme disease</title>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <surname>Meltzer</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <surname>Dennis</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">K</forename>
                  <surname>Orloski</surname>
                </persName>
              </author>
              <idno type="doi">10.3201/eid0503.990302</idno>
              <ptr target="https://doi.org/10.3201/eid0503.990302PMID"/>
            </analytic>
            <monogr>
              <title level="j">Emerg Infect Dis</title>
              <imprint>
                <biblScope unit="volume">5</biblScope>
                <biblScope unit="page">10341168</biblScope>
                <date type="published" when="1999"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b21">
            <monogr>
              <title level="m" type="main">Vaccines for the 21st Century: A Tool for Decision Making. Institute of Medicine</title>
              <author>
                <persName>
                  <forename type="first">K</forename>
                  <surname>Stratton</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <surname>Durch</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <surname>Lawrence</surname>
                </persName>
              </author>
              <imprint>
                <date type="published" when="1999"/>
                <publisher>National Academy Press</publisher>
                <pubPlace>Washington, D.C.</pubPlace>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b22">
            <analytic>
              <title level="a" type="main">The cost-effectiveness of vaccination against Lyme disease</title>
              <author>
                <persName>
                  <forename type="first">N</forename>
                  <forename type="middle">A</forename>
                  <surname>Shadick</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <forename type="middle">H</forename>
                  <surname>Liang</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">C</forename>
                  <forename type="middle">B</forename>
                  <surname>Phillips</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">K</forename>
                  <surname>Fossel</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">K</forename>
                  <forename type="middle">M</forename>
                  <surname>Kuntz</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Arch Intern Med</title>
              <imprint>
                <biblScope unit="volume">161</biblScope>
                <biblScope unit="page">11252114</biblScope>
                <date type="published" when="2001"/>
                <publisher>PMID</publisher>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b23">
            <analytic>
              <title level="a" type="main">Cost-effectiveness analysis of the Lyme disease vaccine</title>
              <author>
                <persName>
                  <forename type="first">E</forename>
                  <forename type="middle">C</forename>
                  <surname>Hsia</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">B</forename>
                  <surname>Chung</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">S</forename>
                  <surname>Schwartz</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <forename type="middle">A</forename>
                  <surname>Albert</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">B C</forename>
                </persName>
              </author>
              <idno type="doi">10.1002/art.10270</idno>
              <ptr target="https://doi.org/10.1002/art.10270PMID"/>
            </analytic>
            <monogr>
              <title level="j">Arthritis Rheum</title>
              <imprint>
                <biblScope unit="volume">46</biblScope>
                <biblScope unit="page">12115198</biblScope>
                <date type="published" when="2002"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b24">
            <analytic>
              <title level="a" type="main">Empiric antibiotic treatment of erythema migrans-like skin lesions as a function of geography: a clinical and cost effectiveness modeling study</title>
              <author>
                <persName>
                  <forename type="first">P</forename>
                  <forename type="middle">M</forename>
                  <surname>Lantos</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <forename type="middle">J</forename>
                  <surname>Brinkerhoff</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">G</forename>
                  <forename type="middle">P</forename>
                  <surname>Wormser</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <surname>Clemen</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">P</forename>
                  <forename type="middle">M L</forename>
                </persName>
              </author>
              <idno type="doi">10.1089/vbz.2013.1365</idno>
              <ptr target="https://doi.org/10.1089/vbz.2013.1365PMID"/>
            </analytic>
            <monogr>
              <title level="j">Vector Borne Zoonotic Dis</title>
              <imprint>
                <biblScope unit="volume">13</biblScope>
                <biblScope unit="page">24107201</biblScope>
                <date type="published" when="2013"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b25">
            <analytic>
              <title level="a" type="main">Comparative cost-effectiveness of two-tiered testing strategies for serodiagnosis of lyme disease with noncutaneous manifestations</title>
              <author>
                <persName>
                  <forename type="first">G</forename>
                  <forename type="middle">P</forename>
                  <surname>Wormser</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <surname>Levin</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">S</forename>
                  <surname>Soman</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">O</forename>
                  <surname>Adenikinju</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M V</forename>
                  <surname>Longo</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">A</forename>
                  <surname>Branda</surname>
                </persName>
              </author>
              <idno type="doi">10.1128/JCM.01853-13</idno>
              <ptr target="https://doi.org/10.1128/JCM.01853-13PMID"/>
            </analytic>
            <monogr>
              <title level="j">J Clin Microbiol</title>
              <imprint>
                <biblScope unit="volume">51</biblScope>
                <biblScope unit="page">24068010</biblScope>
                <date type="published" when="2013"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b26">
            <analytic>
              <title level="a" type="main">Utilization and cost of serologic tests for Lyme disease in Maryland</title>
              <author>
                <persName>
                  <forename type="first">G</forename>
                  <forename type="middle">T</forename>
                  <surname>Strickland</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">C</forename>
                  <surname>Karp</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <surname>Mathews</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">C</forename>
                  <forename type="middle">A</forename>
                  <surname>Pena</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">J Infect Dis. United States</title>
              <imprint>
                <biblScope unit="volume">176</biblScope>
                <biblScope from="819" to="821" unit="page"/>
                <date type="published" when="1997"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b27">
            <analytic>
              <title level="a" type="main">A cost-of-illness study of Lyme disease in the United States</title>
              <author>
                <persName>
                  <forename type="first">E</forename>
                  <surname>Maes</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">P</forename>
                  <surname>Lecomte</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">N</forename>
                  <surname>Ray</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">E</forename>
                  <forename type="middle">M</forename>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">P</forename>
                  <forename type="middle">L</forename>
                  <surname>Maes</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">E</forename>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Clin Ther</title>
              <imprint>
                <biblScope unit="volume">20</biblScope>
                <biblScope unit="page">9829450</biblScope>
                <date type="published" when="1998"/>
                <publisher>PMID</publisher>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b28">
            <analytic>
              <title level="a" type="main">Lyme disease-what is the cost for Scotland</title>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">W</forename>
                  <surname>Joss</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <forename type="middle">M</forename>
                  <surname>Davidson</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <surname>Ho-Yen</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <surname>Do</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <surname>Ludbrook</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Public Health. Netherlands</title>
              <imprint>
                <biblScope unit="volume">117</biblScope>
                <biblScope from="264" to="273" unit="page"/>
                <date type="published" when="2003"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b29">
            <analytic>
              <title level="a" type="main">Economic impact of Lyme disease</title>
              <author>
                <persName>
                  <forename type="first">X</forename>
                  <surname>Zhang</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <forename type="middle">I</forename>
                  <surname>Meltzer</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">C</forename>
                  <forename type="middle">A</forename>
                  <surname>Peña</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">B</forename>
                  <surname>Hopkins</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">L</forename>
                  <surname>Wroth</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">D</forename>
                  <surname>Fix</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Emerg Infect Dis. Centers for Disease Control and Prevention</title>
              <imprint>
                <biblScope unit="volume">12</biblScope>
                <biblScope from="653" to="60" unit="page"/>
                <date type="published" when="2006"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b30">
            <analytic>
              <title level="a" type="main">Neuroborreliosis-an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of Sweden</title>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">J</forename>
                  <surname>Henningsson</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">B-E</forename>
                  <surname>Malmvall</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <surname>Ernerudh</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <surname>Matussek</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">P</forename>
                  <surname>Forsberg</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Clin Microbiol Infect. England</title>
              <imprint>
                <biblScope unit="volume">16</biblScope>
                <biblScope from="1245" to="1251" unit="page"/>
                <date type="published" when="2010"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b31">
            <analytic>
              <title level="a" type="main">Evaluating frequency, diagnostic quality, and cost of lyme borreliosis testing in Germany: A retrospective model analysis</title>
              <author>
                <persName>
                  <forename type="first">B</forename>
                  <surname>Lohr</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">I</forename>
                  <surname>Muller</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <surname>Mai</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <forename type="middle">E</forename>
                  <surname>Norris</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">O</forename>
                  <surname>Schoffski</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">K-P</forename>
                  <surname>Hunfeld</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Clin Dev Immunol</title>
              <imprint>
                <biblScope unit="volume">6</biblScope>
                <biblScope from="56" to="62" unit="page"/>
                <date type="published" when="2015"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b32">
            <analytic>
              <title level="a" type="main">A safe and cost-effective approach to treating lyme cardiac disease in an era of health care reform</title>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <surname>Kim</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">S</forename>
                  <forename type="middle">J</forename>
                  <surname>Beldner</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <surname>Jadonath</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">E</forename>
                  <forename type="middle">J</forename>
                  <surname>Altman</surname>
                </persName>
              </author>
              <idno type="doi">10.1111/j.1540-8159.2011.03095.x</idno>
              <ptr target="https://doi.org/10.1111/j.1540-8159.2011.03095.xPMID"/>
            </analytic>
            <monogr>
              <title level="j">PACE-Pacing Clin Electrophysiol</title>
              <imprint>
                <biblScope unit="volume">34</biblScope>
                <biblScope unit="page">21453343</biblScope>
                <date type="published" when="2011"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b33">
            <analytic>
              <title level="a" type="main">Lyme disease testing by large commercial laboratories in the United States</title>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">F</forename>
                  <surname>Hinckley</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">N</forename>
                  <forename type="middle">P</forename>
                  <surname>Connally</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">I</forename>
                  <surname>Meek</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">B</forename>
                  <forename type="middle">J</forename>
                  <surname>Johnson</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <forename type="middle">M</forename>
                  <surname>Kemperman</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">K</forename>
                  <forename type="middle">A</forename>
                  <surname>Feldman</surname>
                </persName>
              </author>
              <idno type="doi">10.1093/cid/ciu397</idno>
              <ptr target="https://doi.org/10.1093/cid/ciu397PMID"/>
            </analytic>
            <monogr>
              <title level="j">Clin Infect Dis</title>
              <imprint>
                <biblScope unit="volume">59</biblScope>
                <biblScope unit="page">24879782</biblScope>
                <date type="published" when="2014"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b34">
            <analytic>
              <title level="a" type="main">Health Care Costs, Utilization and Patterns of Care following Lyme Disease</title>
              <author>
                <persName>
                  <forename type="first">E</forename>
                  <forename type="middle">R</forename>
                  <surname>Adrion</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <surname>Aucott</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">K</forename>
                  <forename type="middle">W</forename>
                  <surname>Lemke</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">P</forename>
                  <surname>Weiner</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">PLoS One</title>
              <imprint>
                <biblScope unit="volume">10</biblScope>
                <biblScope from="1" to="14" unit="page"/>
                <date type="published" when="2015"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b35">
            <analytic>
              <title level="a" type="main">Epidemiology and cost of hospital care for Lyme borreliosis in Germany: lessons from a health care utilization database analysis</title>
              <author>
                <persName>
                  <forename type="first">B</forename>
                  <surname>Lohr</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">I</forename>
                  <surname>Muller</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <surname>Mai</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <forename type="middle">E</forename>
                  <surname>Norris</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">O</forename>
                  <surname>Schoffski</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">K-P</forename>
                  <surname>Hunfeld</surname>
                </persName>
              </author>
              <idno type="doi">10.1093/eurpub/ckw269</idno>
              <ptr target="https://doi.org/10.1093/eurpub/ckw269PMID"/>
            </analytic>
            <monogr>
              <title level="m">PMID: 25448420 37. van den Wijngaard CC</title>
              <imprint>
                <date type="published" when="2015"/>
                <biblScope unit="volume">6</biblScope>
                <biblScope unit="page">28444236</biblScope>
              </imprint>
            </monogr>
            <note>Eur J Public Health.</note>
          </biblStruct>
          <biblStruct xml:id="b36">
            <analytic>
              <title level="a" type="main">Initial and long-term costs of patients hospitalized with West Nile virus disease</title>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">E</forename>
                  <surname>Staples</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <forename type="middle">B</forename>
                  <surname>Shankar</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">J</forename>
                  <surname>Sejvar</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <forename type="middle">I</forename>
                  <surname>Meltzer</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <surname>Fischer</surname>
                </persName>
              </author>
              <idno type="doi">10.4269/ajtmh.13-0206</idno>
              <ptr target="https://doi.org/10.4269/ajtmh.13-0206PMID"/>
            </analytic>
            <monogr>
              <title level="j">Am J Trop Med Hyg</title>
              <imprint>
                <biblScope unit="volume">90</biblScope>
                <biblScope unit="page">24515937</biblScope>
                <date type="published" when="2014"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b37">
            <analytic>
              <title level="a" type="main">The potential economic burden of Zika in the continental United States</title>
              <author>
                <persName>
                  <forename type="first">B</forename>
                  <forename type="middle">Y</forename>
                  <surname>Lee</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">A</forename>
                  <surname>Alfaro-Murillo</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">A</forename>
                  <forename type="middle">S</forename>
                  <surname>Parpia</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">L</forename>
                  <surname>Asti</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">P</forename>
                  <forename type="middle">T</forename>
                  <surname>Wedlock</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">P</forename>
                  <forename type="middle">J</forename>
                  <surname>Hotez</surname>
                </persName>
              </author>
              <idno type="doi">10.1371/journal.pntd.0005531</idno>
              <ptr target="https://doi.org/10.1371/journal.pntd.0005531PMID"/>
            </analytic>
            <monogr>
              <title level="j">PLoS Negl Trop Dis</title>
              <imprint>
                <biblScope unit="volume">11</biblScope>
                <biblScope unit="page">28448488</biblScope>
                <date type="published" when="2017"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b38">
            <analytic>
              <title level="a" type="main">Evaluating costs of rheumatic diseases: a literature review</title>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <surname>Ruof</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <surname>Hulsemann</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">G</forename>
                  <surname>Stucki</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Curr Opin Rheumatol</title>
              <imprint>
                <biblScope unit="volume">11</biblScope>
                <biblScope unit="page">10319212</biblScope>
                <date type="published" when="1999"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b39">
            <analytic>
              <title level="a" type="main">Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: A review of the literature</title>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <forename type="middle">N</forename>
                  <surname>Tella</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <surname>Feinglass</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <forename type="middle">W</forename>
                  <surname>Chang</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Curr Opin Rheumatol</title>
              <imprint>
                <biblScope unit="volume">15</biblScope>
                <biblScope unit="page">12598799</biblScope>
                <date type="published" when="2001"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b40">
            <analytic>
              <title level="a" type="main">CDC Estimates 300 000 US Cases of Lyme Disease Annually</title>
              <author>
                <persName>
                  <forename type="first">B</forename>
                  <forename type="middle">M</forename>
                  <surname>Kuehn</surname>
                </persName>
              </author>
              <idno type="doi">10.1001/jama.2013.278331</idno>
              <ptr target="https://doi.org/10.1001/jama.2013.278331PMID"/>
            </analytic>
            <monogr>
              <title level="j">JAMA</title>
              <imprint>
                <biblScope unit="volume">310</biblScope>
                <biblScope unit="page">24045727</biblScope>
                <date type="published" when="2013"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b41">
            <analytic>
              <title level="a" type="main">Need for a New Lyme Disease Vaccine</title>
              <author>
                <persName>
                  <forename type="first">S</forename>
                  <forename type="middle">A</forename>
                  <surname>Plotkin</surname>
                </persName>
              </author>
              <idno type="doi">10.1056/NEJMp1607146</idno>
              <ptr target="https://doi.org/10.1056/NEJMp1607146PMID"/>
            </analytic>
            <monogr>
              <title level="j">N Engl J Med</title>
              <imprint>
                <biblScope unit="volume">375</biblScope>
                <biblScope unit="page">27602662</biblScope>
                <date type="published" when="2016"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b42">
            <analytic>
              <title level="a" type="main">A scoping review of Lyme disease research relevant to public health</title>
              <author>
                <persName>
                  <forename type="first">J</forename>
                  <forename type="middle">D</forename>
                  <surname>Greig</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">I</forename>
                  <surname>Young</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">S</forename>
                  <surname>Harding</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <surname>Mascarenhas</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">L</forename>
                  <forename type="middle">A</forename>
                  <surname>Waddell</surname>
                </persName>
              </author>
              <idno type="doi">10.14745/ccdr.v44i10a03</idno>
              <ptr target="https://doi.org/10.14745/ccdr.v44i10a03"/>
            </analytic>
            <monogr>
              <title level="j">Canada Commun Dis Rep</title>
              <imprint>
                <biblScope unit="volume">44</biblScope>
                <biblScope from="243" to="256" unit="page"/>
                <date type="published" when="2018"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b43">
            <analytic>
              <title level="a" type="main">The continued rise of Lyme disease in Ontario</title>
              <author>
                <persName>
                  <forename type="first">M</forename>
                  <forename type="middle">P</forename>
                  <surname>Nelder</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">S</forename>
                  <surname>Wijayasri</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">C</forename>
                  <forename type="middle">B</forename>
                  <surname>Russell</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">Johnson</forename>
                  <surname>Ko</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">K</forename>
                  <surname>Cronin</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">S</forename>
                  <surname>Johnson</surname>
                </persName>
              </author>
            </analytic>
            <monogr>
              <title level="j">Can Commun Dis Rep</title>
              <imprint>
                <biblScope unit="volume">44</biblScope>
                <biblScope from="231" to="236" unit="page"/>
                <date type="published" when="2018"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b44">
            <analytic>
              <title level="a" type="main">WHO Guide for standardisation of economic evaluations of immunization programmes</title>
              <author>
                <persName>
                  <forename type="first">D</forename>
                  <forename type="middle">G</forename>
                  <surname>Walker</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">R</forename>
                  <surname>Hutubessy</surname>
                </persName>
              </author>
              <author>
                <persName>
                  <forename type="first">P</forename>
                  <surname>Beutels</surname>
                </persName>
              </author>
              <idno type="doi">10.1016/j.vaccine.2009.06.035</idno>
              <ptr target="https://doi.org/10.1016/j.vaccine.2009.06.035PMID"/>
            </analytic>
            <monogr>
              <title level="j">Vaccine</title>
              <imprint>
                <biblScope unit="volume">28</biblScope>
                <biblScope unit="page">19567247</biblScope>
                <date type="published" when="2010"/>
              </imprint>
            </monogr>
          </biblStruct>
          <biblStruct xml:id="b45">
            <monogr>
              <title level="m" type="main">The guidelines manual | Guidance and guidelines | NICE</title>
              <ptr target="https://www.nice.org.uk/process/pmg6/chapter/assessing-cost-effectiveness"/>
              <imprint/>
              <respStmt>
                <orgName>National Institute for Health and Care Excellence</orgName>
              </respStmt>
            </monogr>
          </biblStruct>
        </listBibl>
      </div>
    </back>
  </text>
</TEI>
